L26/P-163 Carrier-assisted vitrification device: driving a new era of standardized oocyte cryopreservation practice
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.499 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von T.E. Wang und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does implementing a carrier-assisted vitrification device reduce inter-operator variability and improve reproducibility compared with conventional manual vitrification workflows? Summary answer Carrier-assisted vitrification effectively eliminates temporal drift (128 s vs. 1.6 s) and standardizes microdroplet size (0.84 ± 0.23 mm² vs. 0.61 ± 0.01 mm²). What is known already Oocyte vitrification is a cornerstone of female fertility preservation; however, the current protocols are hindered by human factors, introducing critical technical variables. Firstly, manual batch processing creates a “temporal drift”; first-loaded oocytes face prolonged cryoprotectant exposure compared to the last, risking cumulative toxicity. Furthermore, intra-operator variability in microdroplet volumes (0.1–0.5 µL) directly affects cooling and warming kinetics, elevating the risk of devitrification and compromising oocyte survival, even within the same batch. These limitations highlight the urgent need for standardized vitrification to minimize operator-dependent variability and ensure consistent, reproducible oocyte preservation outcomes. Study design, size, duration This experimental laboratory study used a randomized comparative design. A total of 240 surplus human MII oocytes were randomly allocated to conventional vitrification (CONV) or the Lenshooke® carrier-assisted device (CB0) and handled by junior and senior embryologists. Four oocytes were processed per run using the Cryotech protocol (equilibration solution [ES]: 13 min; vitrification solution [VS]: 10 s and 30 s). Manipulation time and microdroplet area on the vitrification carrier were recorded. Participants/materials, setting, methods CB0 consists of two domains: a bottom piece with a groove to hold vitrification carriers (e.g., Cryotop, Kitazato, Japan) and a top piece with four funnel-like chambers for oocytes, connected by a single port for medium handling. When assembled, CB0 forms a continuous fluidic channel allowing precise medium manipulation. After final VS aspiration, the lid is opened to leave each oocyte in ∼0.1 µL droplets on the carrier, which is immediately plunged into liquid nitrogen. Main results and the role of chance We measured the manipulation time which is recorded from the first oocyte’s exposure to the next solution until the fourth oocyte. Compared with CONV workflow, the use of the CB0 device significantly reduced manipulation time at all procedural transitions, including ES→VS1, VS1→VS2, and VS2→carrier. The cumulative manipulation time was dramatically shorter with CB0 (1.6 ± 0.2 s) than with CONV (128.8 ± 52.2 s). The difference of temporal effect is exacerbated at the transfer from the final VS to the carrier (CONV: 63.7±26.9 s vs. CB0: 0.6±0.1 s). In contrast to the conventional manual process, which is technically demanding and requires precise pipetting and droplet formation, the CB0 uses a pre-molded chamber design in which the microdroplet is spontaneously produced upon lid removal. In addition to time efficiency, CB0 significantly standardized microdroplet formation. The microdroplet area on the vitrification carrier was smaller and more uniform in the CB0 group compared with CONV, which exhibited larger variability in droplet size (CONV: 0.84±0.23 mm² vs. CB0: 0.61±0.01 mm²). Together, these results demonstrate that CB0 effectively standardizes both manipulation time and microdroplet production, reducing operator-dependent variability during vitrification and improving procedural reproducibility. Limitations, reasons for caution The clinical benefits of the CB0 implement remain to be validated, including key outcomes such as oocyte survival, fertilization efficiency, and blastocyst development. Wider implications of the findings Synchronized medium exchange standardizes the procedures, enhances laboratory consistency, and improves reproducibility CB0 also offers reduced cryoprotectant use, lowering costs and toxicity risks. This approach can streamline staff training, optimize resource allocation, and establish consistent quality standards across operators and centers, ultimately supporting improved patient outcomes and operational efficiency. Trial registration number No
Zitieren
APA
Wang, T., Huang, C., Chen, C., Lee, C., Hsu, C., & Lee, M. (2026). L26/P-163 Carrier-assisted vitrification device: driving a new era of standardized oocyte cryopreservation practice. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.499
Vancouver
Wang T, Huang C, Chen C, Lee C, Hsu C, Lee M. L26/P-163 Carrier-assisted vitrification device: driving a new era of standardized oocyte cryopreservation practice. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.499
BibTeX
@article{Wang2026,
author = {Wang, T.E. and Huang, C.C. and Chen, C.H. and Lee, C.I. and Hsu, C.T. and Lee, M.S.},
title = {L26/P-163 Carrier-assisted vitrification device: driving a new era of standardized oocyte cryopreservation practice},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.499}
}
EUVIMED